Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Prime Medicine, Inc. (PRME)
USD3.42
-0.05 (-1.44%)
US NASDAQ Healthcare Biotechnology
Address
21 Erie Street 2139
Cambridge, MA, US
Cambridge, MA, US
CEO
Allan Reine
Website
primemedicine.com
IPO
2022-10-20
CIK 1894562 ISIN US74168J1016
Description
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
News Sentiment (7d)
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.42
-0.05 (-1.44%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
2.27
Float Shares
59.15M
Free Float %
32.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.85% | +2.80% | -9.84% | +0.00% | -0.90% | -4.90% | +159.84% | -74.42% | -78.53% | -78.53% | -78.53% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (9 ratings, all time)
Buy
Price Targets & DCF
Current price
3.42
Low
12.00
+250.9%
Consensus
17.25
+404.4%
Median
17.00
+397.1%
High
23.00
+572.5%
Ratings Trend (MoM)
69% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 8 | 0 |
| Hold | 4 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 4 |
17.25
+404.4%
|
Quality scores
Altman Z-Score
-4.69
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+55.3% ★ Q1'26: -41.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+18.3% Q1'26: +29.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-4,439.3% Q1'26: -5,014.5% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-4,342.4% Q1'26: -5,917.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-337.4% Q1'26: -363.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+25.4% Q1'26: +35.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.59× Q1'26: -0.59× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 8 EPS Ana. |
Dec 2027 6 Rev. Ana. 7 EPS Ana. |
Dec 2028 9 Rev. Ana. 8 EPS Ana. |
Dec 2029 4 Rev. Ana. 6 EPS Ana. |
Dec 2030 4 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 4.00M (-100.0%)
|
—
est: 591.0K (-100.0%)
|
2.98M
est: 11.55M (-74.2%)
|
4.63M
est: 4.97M (-6.8%)
|
12.92M
8.35M – 19.10M
+160.1% YoY
|
22.51M
3.84M – 56.15M
+74.2% YoY
|
31.19M
8.42M – 71.19M
+38.6% YoY
|
18.36M
4.96M – 41.90M
-41.1% YoY
|
60.06M
16.22M – 137.09M
+227.2% YoY
|
| EBITDA |
-114.32M
est: 1.46M (-7,911.4%)
|
-186.64M
est: 118.2K (-158,002.4%)
|
-196.34M
est: 2.31M (-8,599.5%)
|
-195.76M
est: 993.5K (-19,803.9%)
|
2.58M
1.67M – 3.82M
+160.1% YoY
|
4.50M
768.1K – 11.23M
+74.2% YoY
|
6.24M
1.68M – 14.24M
+38.6% YoY
|
3.67M
991.4K – 8.38M
-41.1% YoY
|
12.01M
3.24M – 27.42M
+227.2% YoY
|
| EBIT |
-116.54M
est: 1.46M (-8,099.5%)
|
-191.29M
est: 118.2K (-161,938.9%)
|
-202.47M
est: 2.31M (-8,864.8%)
|
-201.14M
est: 993.5K (-20,345.8%)
|
2.58M
1.67M – 3.82M
+160.1% YoY
|
4.50M
768.1K – 11.23M
+74.2% YoY
|
6.24M
1.68M – 14.24M
+38.6% YoY
|
3.67M
991.4K – 8.38M
-41.1% YoY
|
12.01M
3.24M – 27.42M
+227.2% YoY
|
| Net Income |
-121.82M
est: -495.75M (+75.4%)
|
-198.13M
est: -204.50M (+3.1%)
|
-195.88M
est: -202.01M (+3.0%)
|
-201.14M
est: -198.37M (-1.4%)
|
-188.50M
-190.76M – -119.63M
+5.0% YoY
|
-144.89M
-183.43M – -106.36M
+23.1% YoY
|
-129.88M
-169.16M – -90.61M
+10.4% YoY
|
-137.16M
-365.86M – -7.00M
-5.6% YoY
|
-119.90M
-319.83M – -6.12M
+12.6% YoY
|
| SGA |
29.82M
est: 16.34M (+82.5%)
|
43.39M
est: 3.68M (+1,079.6%)
|
50.16M
est: 71.88M (-30.2%)
|
52.35M
est: 30.91M (+69.3%)
|
80.42M
51.99M – 118.88M
+160.1% YoY
|
140.06M
23.90M – 349.44M
+74.2% YoY
|
194.09M
52.41M – 443.03M
+38.6% YoY
|
114.24M
30.85M – 260.76M
-41.1% YoY
|
373.76M
100.93M – 853.18M
+227.2% YoY
|
| EPS |
-1.46
est: -4.18 (+65.1%)
|
-2.18
est: -2.16 (-1.0%)
|
-1.65
est: -1.60 (-3.2%)
|
-1.35
est: -1.34 (-0.9%)
|
-1.00
-1.28 – -0.80
+25.3% YoY
|
-0.91
-1.23 – -0.71
+8.8% YoY
|
-0.81
-1.14 – -0.61
+11.1% YoY
|
-0.92
-2.46 – -0.05
-13.8% YoY
|
-0.81
-2.15 – -0.04
+12.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-180.60M
OE per share TTM
-1.14
Owner's Yield
-32.69%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
2,493.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
62
Total invested
42.37M
Insider transactions (90d)
0
Beneficial owners (>5%)
24
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Robert Nelsen | 15.47M | 12.90% | 16.1K | 15.46M | 16.1K | 15.46M | IN | — | 2024-02-22 | ↗ |
| 2 | ARCH Venture Fund X Overage, L.P. | 15.46M | 12.90% | — | 15.46M | — | 15.46M | PN | — | 2024-02-22 | ↗ |
| 3 | ARCH Venture Fund X, L.P. | 15.46M | 12.90% | — | 15.46M | — | 15.46M | PN | — | 2024-02-22 | ↗ |
| 4 | ARCH Venture Fund XII, L.P. | 15.46M | 12.90% | — | 15.46M | — | 15.46M | PN | — | 2024-02-22 | ↗ |
| 5 | ARCH Venture Partners X Overage, L.P. | 15.46M | 12.90% | — | 15.46M | — | 15.46M | PN | — | 2024-02-22 | ↗ |
| 6 | ARCH Venture Partners X, L.P. | 15.46M | 12.90% | — | 15.46M | — | 15.46M | PN | Delaware | 2024-02-22 | ↗ |
| 7 | ARCH Venture Partners XII, L.P. | 15.46M | 12.90% | — | 15.46M | — | 15.46M | PN | — | 2024-02-22 | ↗ |
| 8 | Keith Crandell | 15.46M | 12.90% | — | 15.46M | — | 15.46M | IN | — | 2024-02-22 | ↗ |
| 9 | Kristina Burow | 15.46M | 12.90% | — | 15.46M | — | 15.46M | IN | — | 2024-02-22 | ↗ |
| 10 | Steven Gillis | 15.46M | 12.90% | — | 15.46M | — | 15.46M | IN | — | 2024-02-22 | ↗ |
| 11 | Alphabet Holdings LLC | 13.28M | 13.70% | — | 13.28M | — | — | OO | — | 2023-02-10 | ↗ |
| 12 | XXVI Holdings Inc. | 13.28M | 13.70% | — | 13.28M | — | — | CO | — | 2023-02-10 | ↗ |
| 13 | Crandell | 12.26M | 12.60% | — | 12.26M | — | 12.26M | IN | — | 2023-02-13 | ↗ |
| 14 | Gillis | 12.26M | 12.60% | — | 12.26M | — | 12.26M | IN | — | 2023-02-13 | ↗ |
| 15 | Venture Fund X Overage, L.P. | 12.26M | 12.60% | — | 12.26M | — | 12.26M | PN | — | 2023-02-13 | ↗ |
| 16 | Venture Fund X, L.P. | 12.26M | 12.60% | — | 12.26M | — | 12.26M | PN | — | 2023-02-13 | ↗ |
| 17 | Venture Partners X Overage, L.P. | 12.26M | 12.60% | — | 12.26M | — | 12.26M | PN | — | 2023-02-13 | ↗ |
| 18 | Venture Partners X, L.P. | 12.26M | 12.60% | — | 12.26M | — | 12.26M | PN | — | 2023-02-13 | ↗ |
| 19 | GV 2019 GP, L.L.C. | 11.52M | 11.90% | — | 11.52M | — | — | OO | — | 2023-02-10 | ↗ |
| 20 | GV 2019, L.P. | 11.52M | 11.90% | — | 11.52M | — | — | PN | — | 2023-02-10 | ↗ |
| 21 | Bristol-Myers Squibb Company | 11.01M | 8.40% | 11.01M | — | 11.01M | — | CO | Delaware | 2024-10-04 | ↗ |
| 22 | GV 2021 GP, L.P. | 1.76M | 1.80% | — | 1.76M | — | — | PN | — | 2023-02-10 | ↗ |
| 23 | GV 2021, L.P. | 1.76M | 1.80% | — | 1.76M | — | — | PN | — | 2023-02-10 | ↗ |
| 24 | 56-0939887 | 505.1K | 53.17% | — | — | — | — | IA, HC | — | 2023-12-13 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
62
-125 vs prev Q
New positions
11
Closed positions
131
Increased
37
Reduced
11
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 1.79M +1.8M (+100.0%) | 6.22B +6.2B (+100.0%) | 1.12% +1.117 pp | 8.59% +8.594 pp | USD3.47 +0.0% | 1 qtrs NEW |
| 2 | ALPHABET INC. | 16.56M +— (+0.0%) | 57.47M -34.3M (-37.4%) | 10.32% -2.502 pp | 2.23% -1.582 pp | USD15.12 -77.1% | 13 qtrs — |
| 3 | BLACKROCK, INC. | 8.27M +2.6M (+46.3%) | 28.69M -2.6M (-8.3%) | 5.15% +0.778 pp | 0.00% 0.000 pp | USD3.95 -12.2% | 6 qtrs — |
| 4 | VANGUARD GROUP INC | 6.47M +1.5M (+31.4%) | 22.44M -4.8M (-17.7%) | 4.03% +0.220 pp | 0.00% 0.000 pp | USD8.62 -59.7% | 13 qtrs — |
| 5 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 6.00M -3.2M (-35.0%) | 20.80M -30.3M (-59.3%) | 3.74% -3.400 pp | 0.01% -0.018 pp | USD5.04 -31.2% | 8 qtrs — |
| 6 | ARK INVESTMENT MANAGEMENT LLC | 5.37M -109.3K (-2.0%) | 18.63M -11.7M (-38.6%) | 3.34% -0.896 pp | 0.12% -0.057 pp | USD7.89 -56.0% | 13 qtrs — |
| 7 | STATE STREET CORP | 5.10M +3.8M (+293.0%) | 17.68M +10.5M (+146.1%) | 3.17% +2.171 pp | 0.00% +0.000 pp | USD4.81 -27.9% | 13 qtrs — |
| 8 | SUMITOMO MITSUI TRUST HOLDINGS, INC. | 3.25M -384.4K (-10.6%) | 11.26M -8.8M (-44.0%) | 2.02% -0.788 pp | 0.01% -0.005 pp | USD9.28 -62.6% | 13 qtrs — |
| 9 | NIKKO ASSET MANAGEMENT AMERICAS, INC. | 3.25M -384.4K (-10.6%) | 11.20M -8.8M (-44.1%) | 2.02% -0.788 pp | 0.13% -0.065 pp | USD9.26 -62.5% | 13 qtrs — |
| 10 | CASDIN CAPITAL, LLC | 3.17M +— (+0.0%) | 10.99M -6.6M (-37.4%) | 1.97% -0.478 pp | 0.68% -0.780 pp | USD5.89 -41.1% | 13 qtrs — |
| 11 | BALYASNY ASSET MANAGEMENT L.P. | 3.12M +3.1M (+6,426.4%) | 10.84M +10.6M (+3,987.8%) | 1.95% +1.910 pp | 0.01% +0.013 pp | USD3.50 -0.9% | 2 qtrs — |
| 12 | WOODLINE PARTNERS LP | 3.00M +362.0 (+0.0%) | 10.42M -6.2M (-37.4%) | 1.87% -0.453 pp | 0.04% -0.038 pp | USD5.54 -37.4% | 2 qtrs — |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 2.63M +861.5K (+48.8%) | 9.12M -667.8K (-6.8%) | 1.64% +0.270 pp | 0.00% 0.000 pp | USD7.35 -52.8% | 13 qtrs — |
| 14 | UBS GROUP AG | 2.44M +2.1M (+700.8%) | 8.47M +6.8M (+401.6%) | 1.52% +1.285 pp | 0.00% +0.001 pp | USD3.56 -2.5% | 13 qtrs — |
| 15 | FMR LLC | 2.18M -636.4K (-22.6%) | 7.55M -8.0M (-51.5%) | 1.36% -0.821 pp | 0.00% 0.000 pp | USD18.28 -81.0% | 13 qtrs — |
| 16 | GOLDMAN SACHS GROUP INC | 1.76M +1.3M (+327.5%) | 6.09M +3.8M (+167.7%) | 1.09% +0.776 pp | 0.00% +0.001 pp | USD3.78 -8.2% | 10 qtrs — |
| 17 | TWO SIGMA INVESTMENTS, LP | 1.63M +1.2M (+264.0%) | 5.65M +3.2M (+128.0%) | 1.02% +0.669 pp | 0.01% +0.004 pp | USD4.02 -13.7% | 10 qtrs — |
| 18 | D. E. SHAW & CO., INC. | 1.55M -664.5K (-30.0%) | 5.38M -6.9M (-56.1%) | 0.97% -0.749 pp | 0.00% -0.004 pp | USD5.54 -37.4% | 2 qtrs — |
| 19 | FARALLON CAPITAL MANAGEMENT LLC | 1.24M -3.5M (-73.9%) | 4.31M -22.0M (-83.6%) | 0.77% -2.904 pp | 0.02% -0.087 pp | USD5.73 -39.4% | 8 qtrs — |
| 20 | MORGAN STANLEY | 1.17M +438.9K (+60.0%) | 4.06M +9.8K (+0.2%) | 0.73% +0.163 pp | 0.00% +0.000 pp | USD4.56 -23.9% | 13 qtrs — |
| 21 | RENAISSANCE TECHNOLOGIES LLC | 1.15M +14.5K (+1.3%) | 3.99M -2.3M (-36.6%) | 0.72% -0.162 pp | 0.01% -0.002 pp | USD4.82 -28.0% | 9 qtrs — |
| 22 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 936.8K +363.7K (+63.4%) | 3.25M +75.5K (+2.4%) | 0.58% +0.140 pp | 0.00% +0.000 pp | USD6.74 -48.5% | 13 qtrs — |
| 23 | NORTHERN TRUST CORP | 842.2K +234.2K (+38.5%) | 2.92M -446.0K (-13.2%) | 0.52% +0.054 pp | 0.00% 0.000 pp | USD8.10 -57.2% | 13 qtrs — |
| 24 | GREENWICH WEALTH MANAGEMENT LLC | 740.0K +20.0K (+2.8%) | 2.57M -1.4M (-35.6%) | 0.46% -0.096 pp | 0.11% -0.084 pp | USD7.97 -56.5% | 12 qtrs — |
| 25 | HRT FINANCIAL LP | 655.4K +433.9K (+195.9%) | 2.27M +1.0M (+85.5%) | 0.41% +0.237 pp | 0.01% +0.003 pp | USD3.87 -10.3% | 5 qtrs — |
| 26 | BANK OF AMERICA CORP /DE/ | 648.0K +537.2K (+484.6%) | 2.25M +1.6M (+266.2%) | 0.40% +0.318 pp | 0.00% +0.000 pp | USD4.29 -19.1% | 13 qtrs — |
| 27 | POINT72 ASSET MANAGEMENT, L.P. | 551.0K +551.0K (+100.0%) | 1.91M +1.9M (+100.0%) | 0.34% +0.343 pp | 0.00% +0.002 pp | USD3.47 +0.0% | 1 qtrs NEW |
| 28 | MOORE CAPITAL MANAGEMENT, LP | 500.0K +— (+0.0%) | 1.74M -1.0M (-37.4%) | 0.31% -0.076 pp | 0.03% -0.013 pp | USD6.76 -48.7% | 13 qtrs — |
| 29 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 471.7K +202.9K (+75.5%) | 1.64M +147.6K (+9.9%) | 0.29% +0.086 pp | 0.00% +0.000 pp | USD4.53 -23.4% | 9 qtrs — |
| 30 | JPMORGAN CHASE & CO | 435.7K +392.3K (+904.2%) | 1.51M +1.3M (+529.0%) | 0.27% +0.238 pp | 0.00% +0.000 pp | USD4.23 -18.0% | 13 qtrs — |
| 31 | AQR CAPITAL MANAGEMENT LLC | 415.8K +1.6K (+0.4%) | 1.44M -851.8K (-37.1%) | 0.26% -0.062 pp | 0.00% -0.001 pp | USD2.23 +55.6% | 7 qtrs — |
| 32 | HIGHTOWER ADVISORS, LLC | 400.1K +66.4K (+19.9%) | 1.39M -460.6K (-24.9%) | 0.25% -0.009 pp | 0.00% -0.001 pp | USD5.66 -38.7% | 11 qtrs — |
| 33 | TWO SIGMA ADVISERS, LP | 383.5K +383.5K (+100.0%) | 1.33M +1.3M (+100.0%) | 0.24% +0.239 pp | 0.00% +0.003 pp | USD3.47 +0.0% | 1 qtrs NEW |
| 34 | BARCLAYS PLC | 363.8K +279.1K (+329.6%) | 1.26M +934.7K (+285.2%) | 0.23% +0.161 pp | 0.00% +0.000 pp | USD3.60 -3.6% | 13 qtrs — |
| 35 | BOLLARD GROUP LLC | 361.1K +— (+0.0%) | 1.25M -748.0K (-37.4%) | 0.23% -0.055 pp | 0.03% -0.016 pp | USD8.86 -60.8% | 9 qtrs — |
| 36 | WELLS FARGO & COMPANY/MN | 294.5K +97.5K (+49.5%) | 1.02M -69.6K (-6.4%) | 0.18% +0.031 pp | 0.00% +0.000 pp | USD4.42 -21.5% | 12 qtrs — |
| 37 | VERITION FUND MANAGEMENT LLC | 291.0K +291.0K (+100.0%) | 1.01M +1.0M (+100.0%) | 0.18% +0.181 pp | 0.00% +0.004 pp | USD3.47 +0.0% | 1 qtrs NEW |
| 38 | NUVEEN, LLC | 251.6K +25.8K (+11.4%) | 873.2K -378.0K (-30.2%) | 0.16% -0.018 pp | 0.00% 0.000 pp | USD2.68 +29.5% | 4 qtrs — |
| 39 | WELLINGTON MANAGEMENT GROUP LLP | 248.2K +42.9K (+20.9%) | 861.3K -276.2K (-24.3%) | 0.15% -0.004 pp | 0.00% +0.000 pp | USD5.18 -33.0% | 2 qtrs — |
| 40 | PEAK6 LLC | 246.9K -6.5K (-2.6%) | 856.7K -547.1K (-39.0%) | 0.15% -0.042 pp | 0.00% -0.001 pp | USD5.54 -37.4% | 2 qtrs — |
| 41 | BANK OF NEW YORK MELLON CORP | 246.8K +49.0K (+24.8%) | 856.3K -239.1K (-21.8%) | 0.15% +0.001 pp | 0.00% 0.000 pp | USD7.77 -55.3% | 13 qtrs — |
| 42 | CHELSEA COUNSEL CO | 227.0K +18.8K (+9.0%) | 787.7K -365.8K (-31.7%) | 0.14% -0.020 pp | 0.34% -0.174 pp | USD3.86 -10.1% | 13 qtrs — |
| 43 | DARK FOREST CAPITAL MANAGEMENT LP | 225.9K +225.9K (+100.0%) | 783.7K +783.7K (+100.0%) | 0.14% +0.141 pp | 0.04% +0.036 pp | USD3.47 +0.0% | 1 qtrs NEW |
| 44 | SQUAREPOINT OPS LLC | 218.0K +178.4K (+450.6%) | 756.6K +537.2K (+244.9%) | 0.14% +0.105 pp | 0.00% +0.001 pp | USD3.34 +3.9% | 3 qtrs — |
| 45 | CITADEL ADVISORS LLC | 204.4K +9.3K (+4.8%) | 709.3K -371.6K (-34.4%) | 0.13% -0.024 pp | 0.00% 0.000 pp | USD3.17 +9.5% | 10 qtrs — |
| 46 | GREEN ALPHA ADVISORS, LLC | 190.9K +530.0 (+0.3%) | 662.4K -392.2K (-37.2%) | 0.12% -0.028 pp | 0.61% -0.411 pp | USD4.36 -20.4% | 11 qtrs — |
| 47 | RAFFERTY ASSET MANAGEMENT, LLC | 187.7K +187.7K (+100.0%) | 651.4K +651.4K (+100.0%) | 0.12% +0.117 pp | 0.00% +0.002 pp | USD3.47 +0.0% | 1 qtrs NEW |
| 48 | IQ EQ FUND MANAGEMENT (IRELAND) LTD | 178.5K +57.7K (+47.8%) | 619.5K -49.6K (-7.4%) | 0.11% +0.018 pp | 0.04% -0.003 pp | USD4.44 -21.8% | 7 qtrs — |
| 49 | JUMP FINANCIAL, LLC | 171.9K +171.9K (+100.0%) | 596.6K +596.6K (+100.0%) | 0.11% +0.107 pp | 0.01% +0.007 pp | USD3.47 +0.0% | 1 qtrs NEW |
| 50 | SWISS NATIONAL BANK | 170.1K +170.1K (+100.0%) | 590.2K +590.2K (+100.0%) | 0.11% +0.106 pp | 0.00% +0.000 pp | USD3.47 +0.0% | 1 qtrs NEW |
| 51 | DEUTSCHE BANK AG\ | 147.9K +15.2K (+11.4%) | 513.4K -222.2K (-30.2%) | 0.09% -0.011 pp | 0.00% 0.000 pp | USD4.41 -21.3% | 13 qtrs — |
| 52 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 134.8K -30.0K (-18.2%) | 467.8K -445.2K (-48.8%) | 0.08% -0.044 pp | 0.01% -0.010 pp | USD2.47 +40.5% | 3 qtrs — |
| 53 | KEYSTONE FINANCIAL GROUP | 129.7K +58.8K (+83.0%) | 449.9K +57.4K (+14.6%) | 0.08% +0.026 pp | 0.03% +0.004 pp | USD4.60 -24.6% | 2 qtrs — |
| 54 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 121.4K +120.3K (+10,557.7%) | 421.2K +414.9K (+6,575.5%) | 0.08% +0.075 pp | 0.00% +0.001 pp | USD3.49 -0.6% | 2 qtrs — |
| 55 | STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 118.4K -8.0K (-6.3%) | 410.9K -289.3K (-41.3%) | 0.07% -0.024 pp | 0.00% -0.002 pp | USD5.54 -37.4% | 2 qtrs — |
| 56 | FIL LTD | 115.6K -727.0 (-0.6%) | 401.1K -243.3K (-37.8%) | 0.07% -0.018 pp | 0.00% 0.000 pp | USD18.58 -81.3% | 13 qtrs — |
| 57 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 115.1K -5.4K (-4.5%) | 398.9K -268.2K (-40.2%) | 0.07% -0.022 pp | 0.00% -0.001 pp | USD3.11 +11.6% | 7 qtrs — |
| 58 | GRAHAM CAPITAL MANAGEMENT, L.P. | 114.7K +114.7K (+100.0%) | 397.9K +397.9K (+100.0%) | 0.07% +0.072 pp | 0.01% +0.010 pp | USD3.47 +0.0% | 1 qtrs NEW |
| 59 | ALLIANCEBERNSTEIN L.P. | 108.7K +— (+0.0%) | 377.2K -225.0K (-37.4%) | 0.07% -0.016 pp | 0.00% 0.000 pp | USD5.48 -36.7% | 11 qtrs — |
| 60 | RHUMBLINE ADVISERS | 108.4K -1.4K (-1.3%) | 376.2K -232.0K (-38.2%) | 0.07% -0.017 pp | 0.00% 0.000 pp | USD8.77 -60.4% | 11 qtrs — |
| 61 | PRICE T ROWE ASSOCIATES INC /MD/ | 104.6K +30.1K (+40.3%) | 363.0K -50.0K (-12.1%) | 0.07% +0.008 pp | 0.00% +0.000 pp | USD10.62 -67.3% | 13 qtrs — |
| 62 | GROUP ONE TRADING, L.P. | 103.2K +103.2K (+100.0%) | 358.1K +358.1K (+100.0%) | 0.06% +0.064 pp | 0.00% +0.001 pp | USD3.47 +0.0% | 1 qtrs NEW |
| 63 | UBS ASSET MANAGEMENT AMERICAS INC | 99.1K +99.1K (+100.0%) | 343.9K +343.9K (+100.0%) | 0.06% +0.062 pp | 0.00% +0.000 pp | USD3.47 +0.0% | 1 qtrs NEW |
| 64 | VIRTU FINANCIAL LLC | 94.8K +82.9K (+701.2%) | 329.0K +263.0K (+398.5%) | 0.06% +0.050 pp | 0.01% +0.009 pp | USD3.35 +3.6% | 3 qtrs — |
| 65 | QUBE RESEARCH & TECHNOLOGIES LTD | 94.7K +94.7K (+100.0%) | 328.5K +328.5K (+100.0%) | 0.06% +0.059 pp | 0.00% +0.000 pp | USD3.47 +0.0% | 1 qtrs NEW |
| 66 | TD ASSET MANAGEMENT INC | 94.1K -86.9K (-48.0%) | 326.7K -676.3K (-67.4%) | 0.06% -0.082 pp | 0.00% -0.001 pp | USD6.05 -42.6% | 13 qtrs — |
| 67 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 86.9K +83.3K (+2,279.0%) | 301.6K +281.4K (+1,390.1%) | 0.05% +0.051 pp | 0.00% +0.000 pp | USD3.56 -2.5% | 13 qtrs — |
| 68 | PALUMBO WEALTH MANAGEMENT LLC | 85.5K -7.0K (-7.6%) | 296.8K -215.8K (-42.1%) | 0.05% -0.018 pp | 0.07% -0.091 pp | USD2.22 +56.3% | 4 qtrs — |
| 69 | DIMENSIONAL FUND ADVISORS LP | 84.1K +84.1K (+100.0%) | 291.7K +291.7K (+100.0%) | 0.05% +0.052 pp | 0.00% +0.000 pp | USD3.47 +0.0% | 1 qtrs NEW |
| 70 | LEGAL & GENERAL GROUP PLC | 80.7K +74.0K (+1,096.1%) | 280.2K +242.8K (+649.2%) | 0.05% +0.045 pp | 0.00% +0.000 pp | USD4.00 -13.3% | 13 qtrs — |
| 71 | JANE STREET GROUP, LLC | 78.4K +40.5K (+106.9%) | 272.0K +62.1K (+29.6%) | 0.05% +0.020 pp | 0.00% +0.000 pp | USD4.03 -13.9% | 3 qtrs — |
| 72 | XTX TOPCO LTD | 72.9K +24.7K (+51.2%) | 253.1K -14.1K (-5.3%) | 0.05% +0.008 pp | 0.01% -0.007 pp | USD2.81 +23.5% | 5 qtrs — |
| 73 | PROFUND ADVISORS LLC | 69.6K +69.6K (+100.0%) | 241.5K +241.5K (+100.0%) | 0.04% +0.043 pp | 0.01% +0.007 pp | USD3.47 +0.0% | 1 qtrs NEW |
| 74 | VIRTUS INVESTMENT ADVISERS, INC. | 64.9K +64.9K (+100.0%) | 225.2K +225.2K (+100.0%) | 0.04% +0.040 pp | 0.06% +0.061 pp | USD3.47 +0.0% | 1 qtrs NEW |
| 75 | JANUS HENDERSON GROUP PLC | 60.9K +60.9K (+100.0%) | 210.4K +210.4K (+100.0%) | 0.04% +0.038 pp | 0.00% +0.000 pp | USD3.47 +0.0% | 1 qtrs NEW |
| 76 | ENGINEERS GATE MANAGER LP | 60.5K +4.9K (+8.8%) | 209.9K -98.1K (-31.9%) | 0.04% -0.005 pp | 0.00% -0.001 pp | USD5.37 -35.4% | 2 qtrs — |
| 77 | WILEY BROS.-AINTREE CAPITAL, LLC | 60.4K +48.5K (+409.4%) | 209.4K +138.8K (+196.5%) | 0.04% +0.028 pp | 0.00% +0.001 pp | USD3.88 -10.6% | 2 qtrs — |
| 78 | METLIFE INVESTMENT MANAGEMENT, LLC | 57.6K +14.6K (+33.9%) | 199.8K -38.4K (-16.1%) | 0.04% +0.003 pp | 0.00% 0.000 pp | USD2.94 +18.0% | 13 qtrs — |
| 79 | INVESCO LTD. | 56.8K -705.3K (-92.5%) | 197.0K -4.0M (-95.3%) | 0.04% -0.555 pp | 0.00% -0.001 pp | USD5.55 -37.5% | 8 qtrs — |
| 80 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 56.1K -6.2K (-9.9%) | 194.6K -150.2K (-43.6%) | 0.03% -0.013 pp | 0.00% +0.001 pp | USD5.54 -37.4% | 4 qtrs — |
| 81 | AMERIPRISE FINANCIAL INC | 54.1K -7.5K (-12.2%) | 187.7K -153.4K (-45.0%) | 0.03% -0.014 pp | 0.00% +0.000 pp | USD5.54 -37.4% | 2 qtrs — |
| 82 | QUADRATURE CAPITAL LTD | 52.9K +42.7K (+419.2%) | 183.4K +127.2K (+226.1%) | 0.03% +0.025 pp | 0.00% +0.001 pp | USD3.87 -10.3% | 4 qtrs — |
| 83 | MILLENNIUM MANAGEMENT LLC | 51.3K -1.4M (-96.4%) | 178.1K -7.7M (-97.7%) | 0.03% -1.066 pp | 0.00% -0.003 pp | USD5.51 -37.0% | 12 qtrs — |
| 84 | CITIGROUP INC | 51.2K +46.1K (+894.5%) | 177.8K +149.2K (+522.9%) | 0.03% +0.028 pp | 0.00% +0.000 pp | USD3.65 -4.9% | 13 qtrs — |
| 85 | TOROSO INVESTMENTS, LLC | 50.2K +50.2K (+100.0%) | 174.3K +174.3K (+100.0%) | 0.03% +0.031 pp | 0.00% +0.000 pp | USD3.47 +0.0% | 1 qtrs NEW |
| 86 | WALLEYE CAPITAL LLC | 46.1K +46.1K (+100.0%) | 160.1K +160.1K (+100.0%) | 0.03% +0.029 pp | 0.00% +0.001 pp | USD3.47 +0.0% | 1 qtrs NEW |
| 87 | MUTUAL ADVISORS, LLC | 45.2K +— (+0.0%) | 156.8K -86.3K (-35.5%) | 0.03% -0.007 pp | 0.00% -0.002 pp | USD2.47 +40.5% | 3 qtrs — |
| 88 | ELEVATE CAPITAL ADVISORS, LLC | 42.7K +42.7K (+100.0%) | 148.1K +148.1K (+100.0%) | 0.03% +0.027 pp | 0.10% +0.098 pp | USD3.47 +0.0% | 1 qtrs NEW |
| 89 | IVYROCK ASSET MANAGEMENT (HK) LTD | 41.8K +— (+0.0%) | 145.0K -86.5K (-37.4%) | 0.03% -0.006 pp | 0.08% -0.023 pp | USD5.54 -37.4% | 2 qtrs — |
| 90 | JONES FINANCIAL COMPANIES LLLP | 40.4K +30.8K (+322.0%) | 140.2K +91.2K (+186.0%) | 0.03% +0.018 pp | 0.00% +0.000 pp | USD3.96 -12.4% | 2 qtrs — |
| 91 | CI PRIVATE WEALTH, LLC | 38.8K +— (+0.0%) | 134.6K -80.3K (-37.4%) | 0.02% -0.006 pp | 0.00% 0.000 pp | USD5.54 -37.4% | 2 qtrs — |
| 92 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 38.7K +38.7K (+100.0%) | 134.3K +134.3K (+100.0%) | 0.02% +0.024 pp | 0.03% +0.033 pp | USD3.47 +0.0% | 1 qtrs NEW |
| 93 | GSA CAPITAL PARTNERS LLP | 38.5K +38.5K (+100.0%) | 134.0K +134.0K (+100.0%) | 0.02% +0.024 pp | 0.01% +0.012 pp | USD3.47 +0.0% | 1 qtrs NEW |
| 94 | IEQ CAPITAL, LLC | 37.1K +469.0 (+1.3%) | 128.9K -74.3K (-36.6%) | 0.02% -0.005 pp | 0.00% 0.000 pp | USD2.10 +65.2% | 4 qtrs — |
| 95 | MARINER, LLC | 36.3K +18.1K (+99.2%) | 125.9K +25.0K (+24.8%) | 0.02% +0.009 pp | 0.00% +0.000 pp | USD4.51 -23.1% | 2 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 84 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | ARK Genomic Revolution ETF ARKG | 1.36% | 17.80M | 0.75% |
| 2 | AXS Green Alpha ETF NXTE | 0.96% | 549.9K | 1.00% |
| 3 | Virtus Biotech Clinical Trials ETF BBC | 0.84% | 482.6K | 0.65% |
| 4 | Global X - Genomics & Biotechnology ETF GNOM | 0.32% | 275.6K | 0.50% |
| 5 | Global X - Genomics & Biotechnology UCITS ETF GNOM.L | 0.31% | 164.7K | 0.50% |
| 6 | Global X - S&P Biotech ETF CURE.AX | 0.18% | 65.9K | 0.45% |
| 7 | State Street SPDR S&P Biotech ETF XBI | 0.18% | 19.81M | 0.35% |
| 8 | iShares Genomics Immunology and Healthcare ETF IDNA | 0.13% | 245.6K | 0.47% |
| 9 | iShares Micro-Cap ETF IWC | 0.08% | 1.18M | 0.60% |
| 10 | Goldman Sachs Innovate Equity ETF GINN | 0.05% | 105.4K | 0.50% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
800.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+800,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-16 | Makhni Svetlana Ni | Officer | A-Award | A | Stock Option (right to buy) | 800,000 | 3.67 | 2.94M | 800,000 | D | ↗ |
| 2026-02-26 | Reine Allan | Director / Officer | A-Award | A | Stock Option (right to buy) | 1,300,000 | 4.38 | 5.69M | 1,300,000 | D | ↗ |
| 2026-02-23 | LEE ANN L. | Officer | A-Award | A | Stock Option (right to buy) | 375,000 | 3.34 | 1.25M | 375,000 | D | ↗ |
| 2026-02-23 | Alenson Carman | Officer | A-Award | A | Stock Option (right to buy) | 140,000 | 3.34 | 467.6K | 140,000 | D | ↗ |
| 2025-08-01 | Schenkein David P | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 4.04 | 181.8K | 45,000 | D | ↗ |
| 2025-08-01 | Reine Allan | Director / Officer | A-Award | A | Stock Option (right to buy) | 850,000 | 4.04 | 3.43M | 850,000 | D | ↗ |
| 2025-08-01 | NELSEN ROBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 3,030,300 | 3.30 | 10.00M | 6,230,300 | I | ↗ |
| 2025-08-01 | Marrazzo Jeffrey D | Director | A-Award | A | Stock Option (right to buy) | 92,000 | 4.04 | 371.7K | 92,000 | D | ↗ |
| 2025-08-01 | LEE ANN L. | Officer | A-Award | A | Stock Option (right to buy) | 180,995 | 4.04 | 731.2K | 180,995 | D | ↗ |
| 2025-08-01 | Kelly Michael Aaron | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 4.04 | 181.8K | 45,000 | D | ↗ |
| 2025-08-01 | GV 2021 GP, L.L.C. | 10% Owner | P-Purchase | A | Common Stock | 1,500,000 | 3.30 | 4.95M | 3,262,440 | I | ↗ |
| 2025-08-01 | Foster-Cheek Kaye I | Director | D-Return | D | Stock Option (right to buy) | 13,510 | 10.92 | 147.5K | 0 | D | ↗ |
| 2025-08-01 | Chung Wendy | Director | A-Award | A | Stock Option (right to buy) | 9,006 | 4.04 | 36.4K | 9,006 | D | ↗ |
| 2025-08-01 | Cahill Thomas | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 4.04 | 181.8K | 45,000 | D | ↗ |
| 2025-08-01 | Alenson Carman | Officer | A-Award | A | Stock Option (right to buy) | 90,498 | 4.04 | 365.6K | 90,498 | D | ↗ |
| 2025-08-01 | ARCH Venture Partners XII, LLC | 10% Owner | P-Purchase | A | Common Stock | 3,030,300 | 3.30 | 10.00M | 6,230,300 | I | ↗ |
| 2025-08-01 | ARCH Venture Partners X, LLC | 10% Owner | P-Purchase | A | Common Stock | 3,030,300 | 3.30 | 10.00M | 6,230,300 | I | ↗ |
| 2025-06-30 | Liu David R. | 10% Owner | P-Purchase | A | Common Stock | 21,000 | 2.52 | 52.8K | 20,240,945 | D | ↗ |
| 2025-06-23 | Liu David R. | 10% Owner | P-Purchase | A | Common Stock | 21,000 | 2.16 | 45.4K | 20,219,945 | D | ↗ |
| 2025-06-16 | Liu David R. | 10% Owner | P-Purchase | A | Common Stock | 21,000 | 1.49 | 31.2K | 20,198,945 | D | ↗ |
| 2025-06-11 | Liu David R. | 10% Owner | P-Purchase | A | Common Stock | 21,000 | 1.60 | 33.6K | 20,177,945 | D | ↗ |
| 2025-06-04 | Schenkein David P | Director | A-Award | A | Stock Option (right to buy) | 55,000 | 1.32 | 72.6K | 55,000 | D | ↗ |
| 2025-06-04 | NELSEN ROBERT | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 55,000 | 1.32 | 72.6K | 55,000 | D | ↗ |
| 2025-06-04 | Marrazzo Jeffrey D | Director | A-Award | A | Stock Option (right to buy) | 55,000 | 1.32 | 72.6K | 55,000 | D | ↗ |
| 2025-06-04 | Kelly Michael Aaron | Director | A-Award | A | Stock Option (right to buy) | 55,000 | 1.32 | 72.6K | 55,000 | D | ↗ |
| 2025-06-04 | Foster-Cheek Kaye I | Director | A-Award | A | Stock Option (right to buy) | 55,000 | 1.32 | 72.6K | 55,000 | D | ↗ |
| 2025-06-04 | Chung Wendy | Director | A-Award | A | Stock Option (right to buy) | 55,000 | 1.32 | 72.6K | 55,000 | D | ↗ |
| 2025-06-04 | Cahill Thomas | Director | A-Award | A | Stock Option (right to buy) | 55,000 | 1.32 | 72.6K | 55,000 | D | ↗ |
| 2025-05-21 | Reine Allan | Director / Officer | P-Purchase | A | Common Stock | 125,000 | 1.18 | 147.2K | 125,000 | D | ↗ |
| 2025-05-21 | LEE ANN L. | Officer | P-Purchase | A | Common Stock | 100,000 | 1.13 | 113.0K | 100,000 | D | ↗ |
| 2025-05-20 | Brudnick Richard | Officer | P-Purchase | A | Common Stock | 20,000 | 1.19 | 23.8K | 20,000 | D | ↗ |
| 2025-05-19 | Reine Allan | Director / Officer | A-Award | A | Stock Option (right to buy) | 2,000,000 | 1.34 | 2.67M | 2,000,000 | D | ↗ |
| 2025-05-19 | Marrazzo Jeffrey D | Director | A-Award | A | Stock Option (right to buy) | 800,000 | 1.34 | 1.07M | 800,000 | D | ↗ |
| 2025-05-08 | Reine Allan | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 6.80 | 510.0K | 850,000 | D | ↗ |
| 2025-05-08 | LEE ANN L. | Officer | A-Award | A | Stock Option (right to buy) | 80,416 | 3.67 | 295.1K | 241,248 | D | ↗ |
| 2025-05-08 | Gottesdiener Keith Michael | Director / Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 8.32 | 832.0K | 300,000 | D | ↗ |
| 2025-02-28 | Gottesdiener Keith Michael | Director / Officer | A-Award | A | Stock Option (right to buy) | 500,000 | 2.52 | 1.26M | 500,000 | D | ↗ |
| 2025-02-27 | Reine Allan | Officer | A-Award | A | Stock Option (right to buy) | 275,000 | 2.42 | 665.5K | 275,000 | D | ↗ |
| 2025-02-27 | LEE ANN L. | Officer | A-Award | A | Stock Option (right to buy) | 275,000 | 2.42 | 665.5K | 275,000 | D | ↗ |
| 2025-02-27 | Goldwasser Meredith | Officer | A-Award | A | Stock Option (right to buy) | 90,500 | 2.42 | 219.0K | 90,500 | D | ↗ |
| 2025-02-27 | Duffield Jeremy | Officer | A-Award | A | Stock Option (right to buy) | 275,000 | 2.42 | 665.5K | 275,000 | D | ↗ |
| 2025-02-27 | Brudnick Richard | Officer | A-Award | A | Stock Option (right to buy) | 225,000 | 2.42 | 544.5K | 225,000 | D | ↗ |
| 2025-02-27 | Alenson Carman | Officer | A-Award | A | Stock Option (right to buy) | 90,500 | 2.42 | 219.0K | 90,500 | D | ↗ |
| 2024-12-05 | Reine Allan | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 6.80 | 510.0K | 775,000 | D | ↗ |
| 2024-12-05 | Gottesdiener Keith Michael | Director / Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 8.32 | 832.0K | 200,000 | D | ↗ |
| 2024-12-05 | Brudnick Richard | Officer | A-Award | A | Stock Option (right to buy) | 19,300 | 7.96 | 153.6K | 57,900 | D | ↗ |
| 2024-10-08 | Gottesdiener Keith Michael | Director / Officer | G-Gift | D | Common Stock | 226,925 | 0.00 | — | 50,241 | I | ↗ |
| 2024-06-12 | Schenkein David P | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 7.68 | 345.6K | 45,000 | — | ↗ |
| 2024-06-12 | NELSEN ROBERT | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 45,000 | 7.68 | 345.6K | 45,000 | — | ↗ |
| 2024-06-12 | Marrazzo Jeffrey D | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 7.68 | 345.6K | 45,000 | — | ↗ |
| 2024-06-12 | Kelly Michael Aaron | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 7.68 | 345.6K | 45,000 | — | ↗ |
| 2024-06-12 | Foster-Cheek Kaye I | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 7.68 | 345.6K | 45,000 | — | ↗ |
| 2024-06-12 | Chung Wendy | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 7.68 | 345.6K | 45,000 | — | ↗ |
| 2024-06-12 | Cahill Thomas | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 7.68 | 345.6K | 45,000 | — | ↗ |
| 2024-06-05 | Gottesdiener Keith Michael | Director / Officer | G-Gift | D | Common Stock | 250,000 | 0.00 | — | 2,310,837 | — | ↗ |
| 2024-05-17 | Reine Allan | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 6.80 | 680.0K | 100,000 | — | ↗ |
| 2024-05-17 | LEE ANN L. | Officer | A-Award | A | Stock Option (right to buy) | 80,416 | 3.67 | 295.1K | 160,832 | — | ↗ |
| 2024-05-17 | Brudnick Richard | Officer | A-Award | A | Stock Option (right to buy) | 19,300 | 7.96 | 153.6K | 38,600 | — | ↗ |
| 2024-02-29 | Marrazzo Jeffrey D | Director | A-Award | A | Stock Option (right to buy) | 250,000 | 8.63 | 2.16M | 250,000 | — | ↗ |
| 2024-02-25 | Gottesdiener Keith Michael | Director / Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 8.32 | 832.0K | 100,000 | — | ↗ |
| 2024-02-21 | LEE ANN L. | Officer | A-Award | A | Stock Option (right to buy) | 180,995 | 8.49 | 1.54M | 180,995 | — | ↗ |
| 2024-02-21 | Goldwasser Meredith | Officer | A-Award | A | Stock Option (right to buy) | 90,498 | 8.49 | 768.3K | 90,498 | — | ↗ |
| 2024-02-21 | Duffield Jeremy | Officer | A-Award | A | Stock Option (right to buy) | 180,995 | 8.49 | 1.54M | 180,995 | — | ↗ |
| 2024-02-21 | Brudnick Richard | Officer | A-Award | A | Stock Option (right to buy) | 135,747 | 8.49 | 1.15M | 135,747 | — | ↗ |
| 2024-02-21 | Alenson Carman | Officer | A-Award | A | Stock Option (right to buy) | 90,498 | 8.49 | 768.3K | 90,498 | — | ↗ |
| 2024-02-20 | GV 2023 GP, L.L.C. | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 3,200,000 | — | ↗ |
| 2024-02-15 | NELSEN ROBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 3,200,000 | 6.25 | 20.00M | 3,200,000 | — | ↗ |
| 2024-02-15 | ARCH Venture Partners XII, LLC | 10% Owner | P-Purchase | A | Common Stock | 3,200,000 | 6.25 | 20.00M | 3,200,000 | — | ↗ |
| 2024-02-15 | ARCH Venture Partners X, LLC | 10% Owner | P-Purchase | A | Common Stock | 3,200,000 | 6.25 | 20.00M | 3,200,000 | — | ↗ |
| 2024-01-17 | Reine Allan | Officer | A-Award | A | Stock Option (right to buy) | 600,000 | 6.80 | 4.08M | 600,000 | — | ↗ |
| 2023-11-11 | Gottesdiener Keith Michael | Director / Officer | G-Gift | D | Common Stock | 7,500 | 0.00 | — | 2,560,837 | — | ↗ |
| 2023-07-21 | Liu David R. | 10% Owner | G-Gift | D | Common Stock | 1,000,000 | 0.00 | — | 20,156,945 | — | ↗ |
| 2023-06-21 | GV 2019 GP, L.L.C. | 10% Owner | S-Sale | D | Common Stock | 19,003 | 14.97 | 284.5K | 0 | — | ↗ |
| 2023-06-20 | GV 2019 GP, L.L.C. | 10% Owner | J-Other | D | Common Stock | 37,405 | 0.00 | — | 10,119,061 | — | ↗ |
| 2023-06-16 | GV 2019 GP, L.L.C. | 10% Owner | J-Other | D | Common Stock | 6,532 | 0.00 | — | 10,156,466 | — | ↗ |
| 2023-06-15 | GV 2019 GP, L.L.C. | 10% Owner | J-Other | D | Common Stock | 66,659 | 0.00 | — | 10,162,998 | — | ↗ |
| 2023-06-14 | Schenkein David P | Director | A-Award | A | Stock Option (right to buy) | 39,062 | 14.83 | 579.3K | 39,062 | — | ↗ |
| 2023-06-14 | NELSEN ROBERT | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 39,062 | 14.83 | 579.3K | 39,062 | — | ↗ |
| 2023-06-14 | Kelly Michael Aaron | Director | A-Award | A | Stock Option (right to buy) | 39,062 | 14.83 | 579.3K | 39,062 | — | ↗ |
| 2023-06-14 | GV 2019 GP, L.L.C. | 10% Owner | J-Other | D | Common Stock | 28,960 | 0.00 | — | 10,229,657 | — | ↗ |
| 2023-06-14 | Foster-Cheek Kaye I | Director | A-Award | A | Stock Option (right to buy) | 39,062 | 14.83 | 579.3K | 39,062 | — | ↗ |
| 2023-06-14 | Chung Wendy | Director | A-Award | A | Stock Option (right to buy) | 39,062 | 14.83 | 579.3K | 39,062 | — | ↗ |
| 2023-06-14 | Cahill Thomas | Director | A-Award | A | Stock Option (right to buy) | 39,062 | 14.83 | 579.3K | 39,062 | — | ↗ |
| 2023-06-13 | GV 2019 GP, L.L.C. | 10% Owner | S-Sale | D | Common Stock | 28,100 | 15.13 | 425.1K | 0 | — | ↗ |
| 2023-06-12 | GV 2019 GP, L.L.C. | 10% Owner | J-Other | D | Common Stock | 16,031 | 0.00 | — | 10,286,717 | — | ↗ |
| 2023-06-09 | GV 2019 GP, L.L.C. | 10% Owner | J-Other | D | Common Stock | 15,672 | 0.00 | — | 10,302,748 | — | ↗ |
| 2023-06-08 | GV 2019 GP, L.L.C. | 10% Owner | J-Other | D | Common Stock | 5,000 | 0.00 | — | 10,318,420 | — | ↗ |
| 2023-06-07 | GV 2019 GP, L.L.C. | 10% Owner | J-Other | D | Common Stock | 15,000 | 0.00 | — | 10,323,420 | — | ↗ |
| 2023-06-06 | GV 2019 GP, L.L.C. | 10% Owner | S-Sale | D | Common Stock | 29,975 | 17.02 | 510.2K | 0 | — | ↗ |
| 2023-06-05 | GV 2019 GP, L.L.C. | 10% Owner | S-Sale | D | Common Stock | 22,434 | 16.70 | 374.6K | 0 | — | ↗ |
| 2023-06-01 | GV 2019 GP, L.L.C. | 10% Owner | S-Sale | D | Common Stock | 44,752 | 14.35 | 642.2K | 471 | — | ↗ |
| 2023-05-31 | GV 2019 GP, L.L.C. | 10% Owner | S-Sale | D | Common Stock | 16,633 | 13.65 | 227.0K | 0 | — | ↗ |
| 2023-05-30 | GV 2019 GP, L.L.C. | 10% Owner | J-Other | D | Common Stock | 16,805 | 0.00 | — | 10,452,685 | — | ↗ |
| 2023-05-26 | GV 2019 GP, L.L.C. | 10% Owner | J-Other | D | Common Stock | 12,602 | 0.00 | — | 10,469,490 | — | ↗ |
| 2023-05-25 | GV 2019 GP, L.L.C. | 10% Owner | S-Sale | D | Common Stock | 23,161 | 13.38 | 310.0K | 0 | — | ↗ |
| 2023-05-24 | GV 2019 GP, L.L.C. | 10% Owner | J-Other | D | Common Stock | 7,900 | 0.00 | — | 10,505,253 | — | ↗ |
| 2023-05-23 | GV 2019 GP, L.L.C. | 10% Owner | S-Sale | D | Common Stock | 43,939 | 14.74 | 647.6K | 0 | — | ↗ |
| 2023-05-22 | GV 2019 GP, L.L.C. | 10% Owner | S-Sale | D | Common Stock | 87,922 | 14.13 | 1.24M | 0 | — | ↗ |
| 2023-05-19 | GV 2019 GP, L.L.C. | 10% Owner | J-Other | D | Common Stock | 63,212 | 0.00 | — | 10,645,014 | — | ↗ |
| 2023-05-18 | GV 2019 GP, L.L.C. | 10% Owner | S-Sale | D | Common Stock | 14,022 | 13.06 | 183.2K | 0 | — | ↗ |
| 2023-05-17 | GV 2019 GP, L.L.C. | 10% Owner | S-Sale | D | Common Stock | 15,000 | 12.77 | 191.6K | 10,735,324 | — | ↗ |
| 2023-05-16 | GV 2019 GP, L.L.C. | 10% Owner | S-Sale | D | Common Stock | 50,649 | 12.59 | 637.7K | 10,750,324 | — | ↗ |
| 2023-05-15 | GV 2019 GP, L.L.C. | 10% Owner | S-Sale | D | Common Stock | 157,952 | 12.74 | 2.01M | 10,800,973 | — | ↗ |
| 2023-05-12 | GV 2019 GP, L.L.C. | 10% Owner | S-Sale | D | Common Stock | 27,290 | 12.72 | 347.2K | 10,958,925 | — | ↗ |
| 2023-05-11 | GV 2019 GP, L.L.C. | 10% Owner | S-Sale | D | Common Stock | 4,807 | 13.79 | 66.3K | 10,986,215 | — | ↗ |
| 2023-05-10 | Marrazzo Jeffrey D | Director | A-Award | A | Stock Option (right to buy) | 92,000 | 14.04 | 1.29M | 92,000 | — | ↗ |
| 2023-05-10 | GV 2019 GP, L.L.C. | 10% Owner | S-Sale | D | Common Stock | 87,397 | 14.03 | 1.23M | 11,012,841 | — | ↗ |
| 2023-05-09 | GV 2019 GP, L.L.C. | 10% Owner | S-Sale | D | Common Stock | 321,238 | 14.08 | 4.52M | 11,100,238 | — | ↗ |
| 2023-05-08 | GV 2019 GP, L.L.C. | 10% Owner | S-Sale | D | Common Stock | 100,772 | 14.13 | 1.42M | 11,421,476 | — | ↗ |
| 2023-04-18 | Goldwasser Meredith | Officer | A-Award | A | Stock Option (right to buy) | 4,690 | 13.63 | 63.9K | 4,690 | — | ↗ |
| 2023-04-18 | Alenson Carman | Officer | A-Award | A | Stock Option (right to buy) | 6,254 | 13.63 | 85.2K | 6,254 | — | ↗ |
| 2023-03-31 | LEE ANN L. | Officer | A-Award | A | Stock Option (right to buy) | 180,995 | 12.30 | 2.23M | 180,995 | — | ↗ |
| 2023-03-31 | Gottesdiener Keith Michael | Director / Officer | A-Award | A | Stock Option (right to buy) | 497,738 | 12.30 | 6.12M | 497,738 | — | ↗ |
| 2023-03-31 | Goldwasser Meredith | Officer | A-Award | A | Stock Option (right to buy) | 90,498 | 12.30 | 1.11M | 90,498 | — | ↗ |
| 2023-03-31 | Duffield Jeremy | Officer | A-Award | A | Stock Option (right to buy) | 180,995 | 12.30 | 2.23M | 180,995 | — | ↗ |
| 2023-03-31 | Brudnick Richard | Officer | A-Award | A | Stock Option (right to buy) | 135,747 | 12.30 | 1.67M | 135,747 | — | ↗ |
| 2023-03-31 | Alenson Carman | Officer | A-Award | A | Stock Option (right to buy) | 90,498 | 12.30 | 1.11M | 90,498 | — | ↗ |
| 2022-10-24 | NELSEN ROBERT | Director | C-Conversion | D | Series A Convertible Preferred Stock | 49,999 | 0.00 | — | 0 | — | ↗ |
| 2022-10-24 | Liu David R. | Director | C-Conversion | A | Common Stock | 321,665 | 0.00 | — | 21,156,945 | — | ↗ |
| 2022-10-24 | GV 2019 GP, L.L.C. | Director | P-Purchase | A | Common Stock | 800,000 | 17.00 | 13.60M | 11,522,248 | — | ↗ |
| 2022-10-24 | FMR LLC | Director | C-Conversion | A | Common Stock | 4,124,375 | 0.00 | — | 4,124,375 | — | ↗ |
| 2022-10-24 | Cahill Thomas | Director | P-Purchase | A | Common Stock | 400,000 | 17.00 | 6.80M | 5,305,679 | — | ↗ |
| 2022-10-24 | ARCH Venture Partners X, LLC | Director | P-Purchase | A | Common Stock | 400,000 | 17.00 | 6.80M | 6,128,297 | — | ↗ |
| 2022-10-19 | Schenkein David P | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-10-19 | NELSEN ROBERT | Director | — | I | Series B Convertible Preferred Stock | 367,175 | 0.00 | — | — | — | ↗ |
| 2022-10-19 | Liu David R. | Director | — | D | Series A Convertible Preferred Stock | 321,665 | 0.00 | — | — | — | ↗ |
| 2022-10-19 | LEE ANN L. | Officer | — | D | Stock Option (right to buy) | 80,416 | 3.67 | 295.1K | — | — | ↗ |
| 2022-10-19 | Kelly Michael Aaron | Director | — | D | Stock Option (right to buy) | 13,510 | 10.54 | 142.4K | — | — | ↗ |
| 2022-10-19 | Gottesdiener Keith Michael | Officer | — | D | Common Stock | 0 | 0.00 | — | 2,568,337 | — | ↗ |
| 2022-10-19 | Goldwasser Meredith | Officer | — | D | Stock Option (right to buy) | 48,250 | 3.67 | 177.1K | — | — | ↗ |
| 2022-10-19 | GV 2019 GP, L.L.C. | Director | — | I | Series B Convertible Preferred Stock | 1,762,440 | 0.00 | — | — | — | ↗ |
| 2022-10-19 | Foster-Cheek Kaye I | Director | — | D | Stock Option (right to buy) | 13,510 | 10.92 | 147.5K | — | — | ↗ |
| 2022-10-19 | FMR LLC | Director | — | I | Series A Convertible Preferred Stock | 98,967 | 0.00 | — | — | — | ↗ |
| 2022-10-19 | Duffield Jeremy | Officer | — | D | Stock Option (right to buy) | 16,083 | 3.67 | 59.0K | — | — | ↗ |
| 2022-10-19 | Chung Wendy | Director | — | D | Stock Option (right to buy) | 13,510 | 10.54 | 142.4K | — | — | ↗ |
| 2022-10-19 | Cahill Thomas | Director | — | I | Series B Convertible Preferred Stock | 1,689,005 | 0.00 | — | — | — | ↗ |
| 2022-10-19 | Brudnick Richard | Officer | — | D | Stock Option (right to buy) | 19,300 | 7.96 | 153.6K | — | — | ↗ |
| 2022-10-19 | Alenson Carman | Officer | — | D | Stock Option (right to buy) | 16,083 | 10.92 | 175.6K | — | — | ↗ |
| 2022-10-19 | ARCH Venture Partners X, LLC | 10% Owner | — | I | Series A Convertible Preferred Stock | 5,361,122 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-9.4K
Shares Outstanding
180.55M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Allan Reine, M.D. Chief Executive Officer | 606.2K | — | — | 2.83M | 402.0K | 57.2K | 3.89M | 72.64% | ↗ |
| 2 | 2025 | Keith Gottesdiener, M.D. Former Chief Executive Officer | 259.6K | — | — | 1.19M | — | 762.4K | 2.21M | 53.71% | ↗ |
| 3 | 2025 | Ann Lee, Ph.D. | 505.4K | — | — | 790.1K | 244.0K | 10.7K | 1.55M | 50.97% | ↗ |
| 4 | 2025 | Jeremy Duffield, M.D., Ph.D., FRCP Former Chief Scientific Officer | 268.3K | — | — | 668.6K | — | 380.9K | 1.32M | 50.74% | ↗ |
| 5 | 2024 | Allan Reine, M.D. Chief Financial Officer | 479.5K | 176.0K | — | 3.70M | 200.0K | 68.5K | 4.62M | 80.02% | ↗ |
| 6 | 2024 | Allan Reine, M.D. Chief Executive Officer | 479.5K | 176.0K | — | 3.70M | 200.0K | 68.5K | 4.62M | 80.02% | ↗ |
| 7 | 2024 | Keith Gottesdiener, M.D. President & Chief Executive Officer | 652.8K | — | — | 1.17M | 395.0K | 32.8K | 2.25M | 51.88% | ↗ |
| 8 | 2024 | Keith Gottesdiener, M.D. Former Chief Executive Officer | 652.8K | — | — | 1.17M | 395.0K | 32.8K | 2.25M | 51.88% | ↗ |
| 9 | 2024 | Jeremy Duffield, M.D., Ph.D., FRCP Former Chief Scientific Officer | 480.4K | — | — | 1.09M | 293.4K | 11.7K | 1.88M | 58.16% | ↗ |
| 10 | 2024 | Jeremy Duffield, M.D., Ph.D., FRCP Chief Scientific Officer | 480.4K | — | — | 1.09M | 293.4K | 11.7K | 1.88M | 58.16% | ↗ |
| 11 | 2023 | Keith Gottesdiener, M.D. President & Chief Executive Officer | 625.0K | — | — | 4.34M | 393.8K | 40.5K | 5.40M | 80.40% | ↗ |
| 12 | 2023 | Ann Lee, Ph.D. Chief Technical Officer | 472.1K | — | — | 1.58M | 198.3K | 14.4K | 2.26M | 69.76% | ↗ |
| 13 | 2023 | Jeremy Duffield, M.D., Ph.D., FRCP Chief Scientific Officer | 465.0K | — | — | 1.58M | 195.3K | 20.3K | 2.26M | 69.89% | ↗ |
| 14 | 2022 | Richard Brudnick Chief Business Officer | 230.0K | — | — | 993.2K | 220.8K | — | 1.44M | 68.78% | ↗ |
| 15 | 2022 | Ann Lee, Ph.D. Chief Technical Officer | 453.9K | — | — | — | 217.9K | 275.5K | 947.3K | 0.00% | ↗ |
| 16 | 2022 | Keith Gottesdiener, M.D. President & Chief Executive Officer | 542.3K | — | — | — | 360.6K | 21.1K | 924.0K | 0.00% | ↗ |
| 17 | 2022 | Jeremy Duffield, M.D., Ph.D., FRCP Chief Scientific Officer | 447.1K | — | — | — | 414.6K | 10.2K | 872.0K | 0.00% | ↗ |
| 18 | 2021 | Ann Lee, Ph.D. Chief Technical Officer | 108.8K | 54.2K | — | 4.14M | — | 8.2K | 4.32M | 96.03% | ↗ |
| 19 | 2021 | Keith Gottesdiener, M.D. President & Chief Executive Officer | 524.0K | 327.5K | — | 2.07M | — | 15.6K | 2.94M | 70.50% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Allan Reine | Chief Executive Officer & Director | 1M | — |
| Keith Michael Gottesdiener | Consultant | 1M | — |
| Svetlana Makhni | Chief Financial Officer | 924.0K | female |
| Ann L. Lee | Chief Technical Officer | 760.0K | — |
| Matthew J. Hawryluk | Chief Business Officer | 680.8K | — |
| Jeffrey D. Marrazzo | Executive Chair | 140.2K | male |
| Niamh Alix | Chief Human Resources Officer | — | female |
| Ryan E. Brown | Chief Legal Officer | — | male |
| David R. Liu | Co-Founder & Member of Scientific Advisory Board | — | — |
| Mohammed Asmal | Chief Medical Officer | — | male |
| Andrew Anzalone | Co-Founder | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PRME
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
